plerixafor
Clinical Trials Overview
2 trials found
About plerixafor
Plerixafor is a CXCR4 antagonist that blocks the interaction between CXCR4 receptors and their ligand CXCL12 (SDF-1). While FDA-approved for stem cell mobilization in hematologic malignancies, plerixafor is being explored in colorectal cancer for its potential to disrupt the tumor microenvironment. The drug aims to reduce immunosuppressive effects within tumors by interfering with chemokine signaling pathways that promote cancer cell survival and metastasis.
Category
Other Medications
Brand Name
Mozobil
Mechanism
Plerixafor selectively binds to CXCR4 receptors, preventing CXCL12-mediated signaling that normally promotes tumor cell proliferation, angiogenesis, and immune evasion. By blocking this chemokine axis, the drug may enhance immune cell infiltration into tumors and reduce the protective stromal environment that supports colorectal cancer progression.
2
Total Trials
0
Recruiting
0
Active
2
Completed
28
Total Enrollment
2
Countries
NCT03277209
Phase 1
Completed
2 patients
Medications:
Plerixafor
A dose escalation trial to assess the safety of plerixafor in patients with advanced pancreatic, high grade serous ovarian and colorectal cancer. To identify the proof of mechanism, by demonstrating alterations in T-cell tumour distribution, ideally ...
United States, United Kingdom
NCT02179970
Phase 1
Completed
26 patients
Medications:
Plerixafor
Pancreatic, ovarian and colorectal cancers are difficult to treat using chemotherapy and immune therapies.Currently most patients are offered treatment with a standard chemotherapy drug depending on their cancer type. Recently, laboratory studies hav...
United Kingdom